William Blair Has Pessimistic View of VKTX FY2025 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Research analysts at William Blair dropped their FY2025 earnings estimates for Viking Therapeutics in a report issued on Wednesday, October 22nd. William Blair analyst A. Hsieh now expects that the biotechnology company will post earnings per share of ($2.66) for the year, down from their prior forecast of ($2.47). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. William Blair also issued estimates for Viking Therapeutics’ Q4 2025 earnings at ($0.86) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.92) EPS, Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($3.72) EPS and FY2027 earnings at ($4.00) EPS.

Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, October 22nd. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.14). During the same period last year, the business earned ($0.22) earnings per share. The firm’s revenue was up .0% on a year-over-year basis.

Other research analysts also recently issued reports about the company. B. Riley raised Viking Therapeutics to a “strong-buy” rating in a report on Thursday. JPMorgan Chase & Co. decreased their target price on Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating on the stock in a report on Friday. Citigroup lifted their price target on Viking Therapeutics from $31.00 to $38.00 and gave the company a “neutral” rating in a report on Thursday, July 24th. HC Wainwright reissued a “buy” rating and set a $102.00 price objective on shares of Viking Therapeutics in a report on Monday, September 29th. Finally, Zacks Research cut shares of Viking Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 21st. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.62.

Viking Therapeutics Stock Up 1.5%

NASDAQ:VKTX opened at $34.42 on Monday. The firm has a market cap of $3.89 billion, a PE ratio of -16.24 and a beta of 0.64. Viking Therapeutics has a 12 month low of $18.92 and a 12 month high of $81.73. The company’s 50-day moving average price is $28.57 and its two-hundred day moving average price is $28.83.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in VKTX. Cambridge Investment Research Advisors Inc. raised its holdings in Viking Therapeutics by 121.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 29,721 shares of the biotechnology company’s stock worth $718,000 after purchasing an additional 16,302 shares during the period. Wealth Management Associates Inc. bought a new stake in shares of Viking Therapeutics in the 1st quarter valued at $241,000. Kingstone Capital Partners Texas LLC acquired a new stake in Viking Therapeutics during the 2nd quarter worth $1,367,000. U.S. Capital Wealth Advisors LLC lifted its holdings in Viking Therapeutics by 77.7% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 63,546 shares of the biotechnology company’s stock worth $1,684,000 after acquiring an additional 27,795 shares in the last quarter. Finally, Wesbanco Bank Inc. grew its stake in Viking Therapeutics by 118.5% in the second quarter. Wesbanco Bank Inc. now owns 52,000 shares of the biotechnology company’s stock valued at $1,378,000 after acquiring an additional 28,200 shares during the period. 76.03% of the stock is currently owned by institutional investors.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.